

# Effects of daidzein on estrogen-receptor-positive and negative pancreatic cancer cells *in vitro*

Jun-Ming Guo, Bing-Xiu Xiao, De-Jian Dai, Qiong Liu, Hong-Hui Ma

**Jun-Ming Guo, Bing-Xiu Xiao, Qiong Liu**, School of Medicine, Ningbo University, Ningbo 315211, Zhejiang Province, China

**De-Jian Dai**, Second Affiliated Hospital of Medical College, Zhejiang University, Huangzhou 310009, Zhejiang Province, China

**Hong-Hui Ma**, School of Life Science and Bioengineering, Ningbo University, Ningbo 315211, Zhejiang Province, China

**Supported by** Scientific Research Fund of Zhejiang Provincial Education Department, No.20010217

**Correspondence to:** Dr. Jun-Ming Guo, School of Medicine, Ningbo University, Ningbo 315211, Zhejiang Province, China. junmingguo@yahoo.com

**Telephone:** +86-574-87600758 **Fax:** +86-574-87608638

**Received:** 2003-08-26 **Accepted:** 2003-09-18

## Abstract

**AIM:** To study the effects of daidzein on human pancreatic cancer cells *in vitro*.

**METHODS:** Human estrogen-receptor (ER)-positive pancreatic cancer cells MiaPaCa-2 and ER-negative pancreatic cancer cells PANC-1 were treated by 0.1  $\mu\text{mol/L}$ , 1  $\mu\text{mol/L}$ , 10  $\mu\text{mol/L}$ , 25  $\mu\text{mol/L}$ , 50  $\mu\text{mol/L}$ , 75  $\mu\text{mol/L}$  and 100  $\mu\text{mol/L}$  of daidzein, respectively. Its antiproliferative effect was studied by MTT assay.

**RESULTS:** Daidzein inhibited the growth of MiaPaCa-2 and PANC-1 cells at the concentrations from 0.1  $\mu\text{mol/L}$  to 100  $\mu\text{mol/L}$ . A dose- and time-dependent manner was found. The  $\text{IC}_{50}$  of daidzein on MiaPaCa-2 and PANC-1 cells was 45  $\mu\text{mol/L}$  and 75  $\mu\text{mol/L}$ , respectively. After MiaPaCa-2 cells were treated by daidzein for 3 d and at the concentrations more than  $\text{IC}_{50}$ , the inhibitory manner was identical and the inhibition appeared a saturation phenomenon, but the inhibitory manner of daidzein on PANC-1 cells was different from that of MiaPaCa-2 cells.

**CONCLUSION:** Daidzein has antiproliferative effects on human estrogen-receptor-positive and negative pancreatic cancer cells, but their mechanisms may be different.

Guo JM, Xiao BX, Dai DJ, Liu Q, Ma HH. Effects of daidzein on estrogen-receptor-positive and negative pancreatic cancer cells *in vitro*. *World J Gastroenterol* 2004; 10(6): 860-863  
<http://www.wjgnet.com/1007-9327/10/860.asp>

## INTRODUCTION

Phytoestrogens are natural compounds, which exhibit estrogen-like activities. They have been thought to have a preventive effect against a wide range of human conditions, including breast cancer, bowel cancer, prostate cancer, colon cancer and other cancers, cardiovascular diseases, brain function, alcohol abuse, osteoporosis and menopausal symptoms<sup>[1-4]</sup>. There are three main classes of phytoestrogens, namely isoflavones, coumestans, and lignans<sup>[5]</sup>. They are widely distributed in soybeans, oil seeds, and vegetables. Soy contains a number of

isoflavones (such as genistein, genistin, daidzein, and biochanin A), which are found to have potential anticancer properties<sup>[6]</sup>. Interestingly, phytoestrogens can not only inhibit the growth of estrogen-receptor (ER)-dependent cancer cells, but also the growth of ER-independent cancer cells<sup>[7]</sup>. The mechanisms of their anticancer effects include induction of apoptosis, alterations of cell cycle distribution, *etc.*<sup>[8,9]</sup>.

The morbidity of pancreatic carcinoma has taken an upward trend all over the world. In Occidental countries, the morbidity of pancreatic carcinoma has increased by 3 to 7 times in nearly thirty years, and pancreatic carcinoma has become one of the ten commonest malignant tumors<sup>[10]</sup>. Only 15% of patients with pancreatic cancer could undergo resection and the overall 5-year survival rate was about 10%<sup>[11]</sup>. In recent years, many advances in the diagnosis and treatment (including surgical and adjuvant treatment) of pancreatic cancer have been achieved<sup>[12-14]</sup>.

Estrogen receptor has been found in many cases of pancreatic tumor tissues and antiestrogen therapy has benefit to some patients with pancreatic cancers<sup>[15,16]</sup>. There is evidence to support the hypothesis that the increased incidence of pancreatic cancer in Western communities might be related to the relatively low dietary content and protective role of naturally occurring plant hormones and related compounds<sup>[17]</sup>. Generally speaking, treatment of pancreatic cancer is still a serious challenge to us<sup>[10]</sup>. The key problem is to seek novel diagnostic methods, effective adjunctive therapy and the mechanism of pathogenesis and progression of pancreatic cancer. Pancreatic cancer is often detected in its late stages. As a result, it is very important to develop new potential chemopreventive and anticancer reagents for pancreatic cancer, especially those from nature. The effects of daidzein, one of the rich compounds in Eastern countries' traditional diet, on human pancreatic cancer cells are unclear. In this study, we observed the effects of daidzein on the growth of human pancreatic cancer cells *in vitro*.

## MATERIALS AND METHODS

### Materials

Daidzein was purchased from Sigma Chemical Co. (St. Louis, MO) and dissolved in dimethylsulfoxide (DMSO). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was from Sigma. RPMI-1640 medium was from Life Technologies (Grand Island, NY). Human pancreatic cancer cell lines MiaPaCa-2 and PANC-1 were obtained from Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki City, Japan.

### Cell culture and treatment

Cells were cultured in plastic flasks or multi-well plates at 37 °C in a humidified atmosphere of 50 ml/L CO<sub>2</sub> and 950 ml/L air with RPMI-1640 medium containing 100 ml/L fetal calf serum, 50 000 U/L penicillin and 50 mg/L streptomycin. The medium was changed every other day. Exponentially growing cells were used in experiments. For quantitative assays of proliferation, 1×10<sup>4</sup> MiaPaCa-2 or PANC-1 cells were seeded in 96-well

plates in regular growth medium. Twenty-four hours later, cells were incubated in the medium with test compounds or 1 ml/L DMSO (as control). There were 7 test groups. Their concentrations of daidzein were 0.1  $\mu\text{mol/L}$ , 1  $\mu\text{mol/L}$ , 10  $\mu\text{mol/L}$ , 25  $\mu\text{mol/L}$ , 50  $\mu\text{mol/L}$ , 75  $\mu\text{mol/L}$  and 100  $\mu\text{mol/L}$ , respectively. After cells were treated for 1 d, 2 d, 3 d, 4 d, 5 d and 6 d, the growth of cells was monitored by MTT assay.

#### MTT assay

Sets of 12 wells were used for each dose and control in this assay. When the growth time reached, 30  $\mu\text{L}$  MTT solution (2 g/L in PBS) was added into each well of a 96-well plate. After cells were treated for 4 h at 37  $^{\circ}\text{C}$ , the medium was removed and then 150  $\mu\text{L}$  DMSO was added into each well to solubilize formazan. After that, the microplate was shaken on a rotary platform for 10 min. Finally, absorbance was measured at 550 nm with a Wellscan (Labsystems, USA). The inhibitive rate (%) =  $(A_{\text{control}} - A_{\text{experiment}}) / A_{\text{control}} \times 100\%$ .


#### Statistics

Statistical analysis was performed using SPSS software 10.0. Student's *t*-test was used to make a statistical comparison between groups. The level of significance was set at  $P < 0.05$ .


## RESULTS

### Morphologic change of the cells

The effects of daidzein on the growth of pancreatic cancer MiaPaCa-2 and PANC-1 cells were tested over a range of concentrations from 0.1  $\mu\text{mol/L}$  to 100  $\mu\text{mol/L}$ . The changes of configuration and number were observed under a microscope (Figures 1, 2). Both pancreatic cancer cells treated by daidzein grew slower than control (Figures 1, 2). The higher the concentration of daidzein, the less the number of cells.




**Figure 1** Morphologic changes of MiaPaCa-2 cells treated by daidzein. A: Control, B: Cells treated by 10  $\mu\text{mol/L}$  of daidzein for 3 d, C: Cells treated by 75  $\mu\text{mol/L}$  of daidzein for 3 d ( $\times 200$ ).



**Figure 2** Morphologic changes of PANC-1 cells treated by daidzein. A: Control, B: Cells treated by 10  $\mu\text{mol/L}$  of daidzein for 3 d, C: Cells treated by 75  $\mu\text{mol/L}$  of daidzein for 3 d ( $\times 200$ ).

### Inhibitory effect of daidzein on estrogen-receptor-positive pancreatic cancer cells

Estrogen-receptor-positive MiaPaCa-2 cells were treated by various concentrations of daidzein for 1 d to 6 d. At the concentrations from 0.1  $\mu\text{mol/L}$  to 100  $\mu\text{mol/L}$ , especially at 50  $\mu\text{mol/L}$ , 75  $\mu\text{mol/L}$ , and 100  $\mu\text{mol/L}$ , daidzein inhibited the growth of cells ( $P < 0.01$ ) in a time-dependent manner (Figure 3). When cells were treated for 3 d, 50% inhibitory rate might be reached. The  $\text{IC}_{50}$  was 45  $\mu\text{mol/L}$ . At the concentrations of more than  $\text{IC}_{50}$ , the inhibitory patterns were identical ( $P > 0.05$ , Figure 3).




**Figure 3** Inhibitory effects of daidzein on growth of estrogen-receptor-positive pancreatic cancer MiaPaCa-2 cells. 0.1  $\mu\text{mol/L}$ , 1  $\mu\text{mol/L}$ , 10  $\mu\text{mol/L}$ , 25  $\mu\text{mol/L}$ , 50  $\mu\text{mol/L}$ , 75  $\mu\text{mol/L}$  and 100  $\mu\text{mol/L}$  of daidzein were used, respectively.

### Inhibitory effect of daidzein on estrogen-receptor-negative pancreatic cancer cells

ER-negative pancreatic cancer PANC-1 cells were treated by daidzein. A dose-dependent effect was observed (Figure 4; 10  $\mu\text{mol/L}$ , 25  $\mu\text{mol/L}$ , 50  $\mu\text{mol/L}$  and 75  $\mu\text{mol/L}$ ,  $P < 0.05$ ;

100  $\mu\text{mol/L}$ ,  $P < 0.01$ ). When cells were treated for 2 d, 50% inhibitory rate might be observed. The  $\text{IC}_{50}$  was 80  $\mu\text{mol/L}$  on day 2 and 75  $\mu\text{mol/L}$  on day 3.



**Figure 4** Inhibitory effects of daidzein on growth of estrogen-receptor-negative pancreatic cancer PANC-1 cells. 0.1  $\mu\text{mol/L}$ , 1  $\mu\text{mol/L}$ , 10  $\mu\text{mol/L}$ , 25  $\mu\text{mol/L}$ , 50  $\mu\text{mol/L}$ , 75  $\mu\text{mol/L}$  and 100  $\mu\text{mol/L}$  of daidzein were used, respectively.

## DISCUSSION

There has been an increase in the incidence of pancreatic cancer recent years<sup>[18-21]</sup>. The pattern of its increase had some similarities to the high incidence of breast cancer in women and prostate cancer in men in Western communities<sup>[17]</sup>. Typical Western diets have a low content of natural plant hormones, phytoestrogens, which are beneficial to our health<sup>[1-6]</sup>. They exerted their anticancer effects by their specific bi-effects, estrogenic and antiestrogenic properties<sup>[22-24]</sup>. On the one hand, they acted as antiestrogens by competing with endogenous estrogens for receptor binding sites, and decrease the promoting effects of high levels of endogenous estrogens<sup>[25]</sup>. On the other hand, they could inhibit the activities of tyrosine protein kinase, DNA topoisomerase, angiogenesis and antioxidant<sup>[26-29]</sup>.

Hormone products were related to the pathological behaviors of several carcinomas (including colorectal carcinoma, gastric carcinoma, pancreatic carcinoma, etc.) and might help to predict the prognosis and effectiveness of endocrine therapy for some kinds of carcinomas<sup>[30-32]</sup>. As to pancreatic carcinoma, there were indications of possible effects of sex hormones<sup>[33]</sup>. The pancreatic cell lines, MiaPaCa-2 and PANC-1, used in our study were ER positive and negative cells, respectively<sup>[34,35]</sup>. We found that daidzein inhibited the growth of both ER positive and negative pancreatic cancer cells. However, their inhibitory patterns were different. For ER-positive cells, MiaPaCa-2, when the concentrations of daidzein were higher than the level of  $\text{IC}_{50}$ , the inhibitory effect would not significantly increase. It indicated that its antiproliferative effect was exerted by binding to ER and appeared a saturation phenomenon. For PANC-1, an ER-negative cell, the saturation phenomenon was not found and the inhibition was in a dose-dependent manner. Its  $\text{IC}_{50}$  was higher than that of MiaPaCa-2, indicating that for the chemoprevention of ER-negative pancreatic cancer, high concentrations of daidzein should be used.

The antiestrogen reagent, tamoxifen was a choice of hormonal therapy for pancreatic cancer<sup>[16,33]</sup>. The favorable response to this therapy and survival of patients were dependent on whether the patients' tumor cells were estrogen receptor positive or not<sup>[16]</sup>. The presence or absence of estrogen receptors was also important in determining the effects of phytoestrogens on pancreatic cancer cells. A report used four kinds of phytoestrogens to study human pancreatic cancer cells showed that equol and coumestrol had anticarcinogenic effects on human ER positive pancreatic cancer Su86.86 cells. However,

they stimulated the growth of human ER negative pancreatic cancer HPAF-11 cells, genistein stimulated the growth of HPAF-11 cells but had little effect on Su86.86 cells. Another phytoestrogen, biochanin A, inhibited the growth of both Su86.86 cells and HPAF-11 cells<sup>[36]</sup>. Our results showed that daidzein, another main phytoestrogen, had inhibitory effects on both ER positive and negative pancreatic cancer cells. As phytoestrogens are a large group of compounds, the possibility of gender differences in response to these reagents may be important in determining their ability to act as chemoprotective reagents for pancreatic cancer.

## REFERENCES

- 1 **Bingham SA**, Atkinson C, Liggins J, Bluck L, Coward A. Phytoestrogens: where are we now? *Br J Nutr* 1998; **79**: 393-406
- 2 **Yamamoto S**, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group. Soy, isoflavones, and breast cancer risk in Japan. *J Natl Cancer Inst* 2003; **95**: 906-913
- 3 **Adlercreutz H**. Phyto-oestrogens and cancer. *Lancet Oncol* 2002; **3**: 364-373
- 4 **Morrissey C**, Watson RW. Phytoestrogens and prostate cancer. *Curr Drug Targets* 2003; **4**: 231-241
- 5 **Peeters PH**, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. *Breast Cancer Res Treat* 2003; **77**: 171-183
- 6 **Zhou JR**, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. *Cancer Res* 1998; **58**: 5231-5238
- 7 **Maggiolini M**, Bonfiglio D, Marsico S, Panno ML, Cenni B, Picard D, Ando S. Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. *Mol Pharmacol* 2001; **60**: 595-602
- 8 **Yanagihara K**, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. *Cancer Res* 1993; **53**: 5815-5821
- 9 **Su SJ**, Yeh TM, Lei HY, Chow NH. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. *Clin Cancer Res* 2000; **6**: 230-236
- 10 **Tan ZJ**, Hu XG, Cao GS, Tang Y. Analysis of gene expression profile of pancreatic carcinoma using cDNA microarray. *World J Gastroenterol* 2003; **9**: 818-823
- 11 **Li YJ**, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. *World J Gastroenterol* 2003; **9**: 368-372
- 12 **Zheng M**, Liu LX, Zhu AL, Qi SY, Jiang HC, Xiao ZY. K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses. *World J Gastroenterol* 2003; **9**: 188-191
- 13 **Shankar A**, Russell RC. Recent advances in the surgical treatment of pancreatic cancer. *World J Gastroenterol* 2001; **7**: 622-626
- 14 **Ghaneh P**, Slavin J, Sutton R, Hartley M, Neoptolemos JP. Adjuvant therapy in pancreatic cancer. *World J Gastroenterol* 2001; **7**: 482-489
- 15 **Singh S**, Baker PR, Poulson R, Wright NA, Sheppard MC, Langman MJ, Neoptolemos JP. Expression of oestrogen receptor and oestrogen-inducible genes in pancreatic cancer. *Br J Surg* 1997; **84**: 1085-1089
- 16 **Horimi T**, Takasaki M, Toki A, Nishimura W, Morita S. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. *Hepatogastroenterology* 1996; **43**: 1225-1229
- 17 **Stephens FO**. The increased incidence of cancer of the pancreas: is there a missing dietary factor? Can it be reversed? *Aust N Z J Surg* 1999; **69**: 331-335
- 18 **Xu HB**, Zhang YJ, Wei WJ, Li WM, Tu XQ. Pancreatic tumor: DSA diagnosis and treatment. *World J Gastroenterol* 1998; **4**: 80-81
- 19 **Zhao XY**, Yu SY, Da SP, Bai L, Guo XZ, Dai XJ, Wang YM. A clinical evaluation of serological diagnosis for pancreatic cancer. *World J Gastroenterol* 1998; **4**: 147-149
- 20 **Guo XZ**, Friess H, Shao XD, Liu MP, Xia YT, Xu JH, Buchler MW.

- KAI1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis. *World J Gastroenterol* 2000; **6**: 866-871
- 21 **Yue H**, Na YL, Feng XL, Ma SR, Song FL, Yang B. Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer. *World J Gastroenterol* 2003; **9**: 377-380
- 22 **So FV**, Guthrie N, Chambers AF, Carroll KK. Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. *Cancer Lett* 1997; **112**: 127-133
- 23 **Shao ZM**, Alpaugh ML, Fontana JA, Barsky SH. Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. *J Cell Biochem* 1998; **69**: 44-54
- 24 **Hopert AC**, Beyer A, Frank K, Strunck E, Wunsche W, Vollmer G. Characterization of estrogenicity of phytoestrogens in an endometrial-derived experimental model. *Environ Health Perspect* 1998; **106**: 581-586
- 25 **Scambia G**, Ranelletti FO, Panici PB, Piantelli M, De Vincenzo R, Ferrandina G, Bonanno G, Capelli A, Mancuso S. Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast-cancer cell lines. *Int J Cancer* 1993; **54**: 462-466
- 26 **Robinson MJ**, Corbett AH, Osheroff N. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. *Biochemistry* 1993; **32**: 3638-3643
- 27 **Spinozzi F**, Pagliacci MC, Migliorati G, Moraca R, Grignani F, Riccardi C, Nicoletti I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. *Leuk Res* 1994; **18**: 431-439
- 28 **Fotsis T**, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L. Genistein, a dietary-derived inhibitor of *in vitro* angiogenesis. *Proc Natl Acad Sci U S A* 1993; **90**: 2690-2694
- 29 **Wei H**, Wei L, Frenkel K, Bowen R, Barnes S. Inhibition of tumor promoter-induced hydrogen peroxide formation *in vitro* and *in vivo* by genistein. *Nutr Cancer* 1993; **20**: 1-12
- 30 **Xin Y**, Li XL, Wang YP, Zhang SM, Zheng HC, Wu DY, Zhang YC. Relationship between phenotypes of cell-function differentiation and pathobiological behavior of gastric carcinomas. *World J Gastroenterol* 2001; **7**: 53-59
- 31 **Zhao XH**, Gu SZ, Liu SX, Pan BR. Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues. *World J Gastroenterol* 2003; **9**: 665-669
- 32 **Yao GY**, Zhou JL, Lai MD, Chen XQ, Chen PH. Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases. *World J Gastroenterol* 2003; **9**: 858-861
- 33 **Theve NO**, Pousette A, Carlstrom K. Adenocarcinoma of the pancreas—a hormone sensitive tumor? A preliminary report on Nolvadex treatment. *Clin Oncol* 1983; **9**: 193-197
- 34 **Kuramoto M**, Yamashita J, Ogawa M. Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. *Cancer* 1995; **75**: 1263-1272
- 35 **Abe M**, Yamashita J, Ogawa M. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation. *Cancer* 2000; **88**: 2000-2009
- 36 **Lyn-Cook BD**, Stottman HL, Yan Y, Blann E, Kadlubar FF, Hammons GJ. The effects of phytoestrogens on human pancreatic tumor cells *in vitro*. *Cancer Lett* 1999; **142**: 111-119

Edited by Zhang JZ and Wang XL Proofread by Xu FM